← Back to all trials
Recruiting
NCT05196087
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Conditions: Breast Cancer, Melanoma, Gastrointestinal Neuroendocrine Tumor
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 800
Sponsor: University Health Network, Toronto
Location: Princess Margaret Cancer Centre Toronto Ontario
Summary
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.
Eligibility Criteria
Inclusion Criteria:
1. Patients with histological confirmation of a solid tumor.
2. Patients must have early stage or locally advanced disease that is planned for or have undergone curative treatment.
3. Patient must be ≥ 18 years old.
4. All patients must have signed and dated an informed consent form.
Exclusion Criteria:
None
Source: ClinicalTrials.gov (NCT05196087). StuddyBuddy aggregates publicly available trial information.
